What is the clinical evidence from this study?

Study design: Review. Population: Atrial standstill.

What does this research mean for the field?

Atrial standstill is the end-stage manifestation of fibrotic atrial cardiomyopathy resulting from diffuse atrial disease or specific genetic mutations, frequently complicated by thromboembolism and requiring pacing and anticoagulation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize the genetic causes, diagnostic features, and therapeutic strategies associated with atrial standstill.

October 1, 2026Heart Rhythm

Atrial Standstill: From Molecular Genetics to Clinical Management — A Narrative Review

View Full Paper

Ask AI

Bookmark

Key result

Atrial standstill carries up to a ~54% thromboembolism rate, typically warranting pacing and anticoagulation.

Population

Patients with Atrial Standstill caused by diffuse atrial myocardial disease, SCN5A loss-of-function, NPPA…

Design

Review

Authors

MLMin Lin XDXiaoqi Deng YXYu Xia

Discussion

Member takes

Implication

Pacing and anticoagulation remain standard for atrial standstill without trial support; leaves open prospective validation of genotype-guided strategies.

Key Points

To synthesize the genetic causes, diagnostic features, and therapeutic strategies associated with atrial standstill.
Narrative review evaluating clinical literature, electrophysiological criteria, genetic pathways, and imaging modalities for atrial standstill.
Atrial standstill represents end-stage fibrotic atrial cardiomyopathy driven by SCN5A, NPPA, or EMD/LMNA mutations, muscular dystrophies, or infiltrative processes.
Diagnosis requires absent P waves, absent atrial electrograms, and lack of electrical capture at maximal pacing output, with thromboembolism complicating 30% to 54% of cases.
Primary clinical management relies on permanent cardiac pacing, systemic anticoagulation, and genotype-guided risk assessment for implantable cardioverter-defibrillator eligibility.

Structured PICO

Population

Patients with Atrial Standstill (AS) caused by diffuse atrial myocardial disease, SCN5A loss-of-function, NPPA, or EMD/LMNA mutations, muscular dystrophies, and infiltrative or idiopathic fibrotic processes.

Atrial standstill is the end-stage of fibrotic atrial cardiomyopathy with a 30-54% thromboembolic risk, requiring management with permanent pacing, anticoagulation, and gene-specific risk stratification.

Limitations

Absence of trials
Unvalidated risk tools
Incomplete genotype-phenotype correlation
absence of trials
unvalidated risk tools
incomplete genotype-phenotype correlation

Cite This Study

Lin et al. (2026) conducted a review in Atrial standstill. Atrial standstill is a fibrotic atrial cardiomyopathy complicated by thromboembolism in 30-54% of cases, requiring permanent pacing and anticoagulation despite an absence of clinical trials.

synapsesocial.com/papers/6abe35f2bdd7597321d9a4f0 https://doi.org/10.1016/j.hrthm.2026.09.030

View Full Paper

Ask AI

Bookmark

Implication

Pacing and anticoagulation remain standard for atrial standstill without trial support; leaves open prospective validation of genotype-guided strategies.

Atrial Standstill: From Molecular Genetics to Clinical Management — A Narrative Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Atrial Standstill: From Molecular Genetics to Clinical Management — A Narrative Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider